Press Enter to search
Blood collection devices sit at the intersection of patient safety, occupational health, and diagnostic accuracy. As regulatory expectations continue to evolve, laboratories and healthcare facilities must ensure that the devices they use are not only clinically effective, but also fully compliant with U.S. and applicable global standards. In 2026, regulators are placing increased emphasis on risk management, labeling clarity, material safety, and post-market oversight — making regulatory literacy a practical necessity, not just a procurement concern.
This overview breaks down the key regulatory considerations labs must understand to remain compliant, audit-ready, and protected when selecting and using blood collection devices.
Blood collection devices are classified as medical devices and are therefore subject to oversight intended to protect patients and healthcare workers alike. Regulatory non-compliance can expose facilities to audit findings, liability risk, and supply chain disruptions — particularly as inspectors increasingly evaluate not just whether devices are approved, but whether they are used in accordance with their Instructions for Use (IFU).
In recent years, enforcement has expanded beyond manufacturers to include how facilities select, educate on, and document the use of safety-engineered devices. This shift makes it essential for labs to understand the regulatory framework behind the products they rely on every day.
Beyond FDA oversight, occupational safety requirements play a critical role in blood collection compliance. The Occupational Safety and Health Administration requires healthcare employers to reduce exposure to bloodborne pathogens through engineering controls whenever feasible. This includes the use of safety-engineered sharps devices rather than conventional needles.
In practical terms, this means labs must evaluate and document the use of safety blood collection devices, especially when alternatives exist. Products such as the RELI® Push Button Safety Blood Collection Set support compliance by incorporating intuitive, one-handed needle in-vein safety activation designed to reduce needlestick injuries during and after collection.
Facilities should also maintain records demonstrating device evaluation, staff training, and periodic review — all common audit touchpoints.
In addition to traditional blood collection devices, laboratories should also be aware of mutli-use products that serve dual purposes for venipuncture and short-term infusion. The RELI® Safety Slide™ Blood Collection/Infusion Sets are engineered with a sliding safety shield and flexible, color-coded wings that enhance tactile feedback and ease of use. These sets offer one- or two-hand irreversible safety activation with an audible click, supporting OSHA compliance by reducing needlestick risk and aligning with regulatory expectations for safety-engineered sharps devices.
From a compliance perspective, infusion-style blood collection sets must also meet labeling and intended-use requirements similar to other blood collection devices. Like other Class II regulated products, they are intended for venous blood collection and require use under the manufacturer’s Instructions for Use. Ensuring that staff are trained on both the blood collection and short-term fluid administration indications — and that documentation reflects this training — helps facilities demonstrate adherence to IFU and post-market vigilance standards during audits.
Regulatory compliance does not stop at device selection. Labeling and Instructions for Use are legally binding components of a medical device’s clearance. Using a device outside its intended use — even unintentionally — can place a facility out of compliance and increase risk of injury to the patient.
In 2026, inspectors are paying closer attention to whether staff are trained on current IFUs and whether devices are used consistently with manufacturer guidance. This includes proper activation of safety mechanisms, approved transfer methods, and compatible components.
For example, when syringe draws are clinically necessary, using a closed transfer system consistent with labeling helps preserve both safety and compliance. MYCO Medical’s blood transfer devices are designed to support closed, needle-free transfer workflows that align with IFU and safety expectations.
Blood collection devices come into direct or indirect contact with blood and tissue, making material safety a critical regulatory focus. Manufacturers must demonstrate biocompatibility in accordance with internationally recognized standards, including those developed by the International Organization for Standardization.
For labs, this translates into confidence that device materials have been evaluated for cytotoxicity, sensitization, and irritation. While biocompatibility testing is a manufacturer responsibility, facilities should source devices from reputable suppliers that maintain transparent documentation and quality systems.
Regulatory responsibility does not end once a device is approved and purchased. Manufacturers are required to monitor post-market performance and report adverse events, but facilities also play a role by documenting incidents and reporting, device failures, and user feedback.
In 2026, regulators increasingly expect healthcare organizations to have clear processes for reporting device-related issues internally and to suppliers. Maintaining incident logs, participating in product evaluations, and responding promptly to recalls or field safety notices are all part of a compliant post-market posture.
Being audit-ready is less about memorizing regulations and more about demonstrating consistent, defensible practices. Inspectors typically look for evidence that facilities:
Standardizing on safety-engineered solutions, such as MYCO’s Safety Blood Collection Portfolio, can simplify compliance by reducing variation and supporting consistent technique across staff and shifts.
Regulatory expectations for blood collection devices are becoming more integrated, linking patient safety, worker protection, and quality management into a single compliance framework. Labs that proactively align device selection, training, and documentation with regulatory standards are better positioned to pass audits, protect staff, and maintain uninterrupted operations.
Rather than viewing compliance as a constraint, forward-thinking facilities treat it as a quality strategy — one that reinforces safety, consistency, and trust in every blood draw.
Regulatory standards for blood collection devices are not static, and 2026 brings heightened expectations around safety engineering, labeling adherence, and post-market vigilance. By understanding the regulatory landscape and partnering with suppliers that prioritize compliance-ready design, laboratories can stay audit-ready while supporting safe, effective blood collection practices.
To learn more about RELI® blood collection solutions or to speak with a MYCO Medical representative about compliance-focused device selection, visit our Contact Us page.
